Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

The most common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea most commonly happens when first starting BYETTA, but may become less over time.

These are not all the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For additional important safety information about BYETTA, please see the full Prescribing Information (http://pi.lilly.com/us/byetta-pi.pdf) and Medication Guide (http://pi.lilly.com/us/byetta-ppi.pdf).

About Amylin, Lilly and Alkermes

Amylin, Lilly and Alkermes are working together to develop BYDUREON, a subcutaneous injection of exenatide for the treatment of type 2 diabetes based on Alkermes' proprietary Medisorb® technology for long-acting medications. BYDUREON is not currently approved by any regulatory agencies.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... ... Confocal High-Content Imaging System. This transformative system fits a broad range of ... such as spheroids, tissues, and organisms. , The ImageXpress Micro Confocal ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma ... Equine cervical facet joint problems can be caused by injuries and abnormalities of ... of nerve roots or of the spinal cord itself. This can manifest itself ...
(Date:9/1/2015)... ... ... Knowledgent , the data and analytics firm, today announced a new ... the healthcare industry. , As the Internet of Things (IoT) continues to grab headlines ... years as more entities become technology enabled through Electronic Medical Records (EMRs). , With ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
Breaking Biology Technology:ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
... 8 Edwards Lifesciences,Corporation (NYSE: EW ), the ... the company will celebrate a number of cardiac surgery,milestones ... the American,Association for Thoracic Surgery (AATS), May 10-14 in ... -- which this year celebrates,its 50th anniversary of partnering ...
... Listing and Attract Additional Investors ... as Company Enters Next Growth Phase, SAN DIEGO, May 8 ... (ICG),technology, today announced the reverse split of 1 for 7 shares ... Company,s,Annual Shareholders Meeting earlier today., The record date for the ...
... ... U.S. ThermaCool NXT System Sales ... THRM ), a leader in non-invasive tissue tightening in the ... 31, 2008., Revenue for the first quarter of 2008 was ...
Cached Biology Technology:Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 2Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 3Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 4CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 2CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 3Thermage Announces First Quarter 2008 Financial Results 2Thermage Announces First Quarter 2008 Financial Results 3Thermage Announces First Quarter 2008 Financial Results 4Thermage Announces First Quarter 2008 Financial Results 5Thermage Announces First Quarter 2008 Financial Results 6Thermage Announces First Quarter 2008 Financial Results 7Thermage Announces First Quarter 2008 Financial Results 8Thermage Announces First Quarter 2008 Financial Results 9
(Date:8/4/2015)... , Aug. 04, 2015 ... http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition of ... (Hardware, Software, and Service), Sub-Segment (Computer Forensics, ... Forensics), Tool Types, Service, Vertical and Region ... to their offering. By Component ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... May 9, 2013, New York, NY and San Diego, CA ... Epigenome Roadmap Project has published a sweeping analysis in the ... genes are turned on and off to direct early human ... Cancer Research, Joseph Ecker of The Salk Institute for Biological ...
... WASHINGTON , May 9, 2013 ... a solution that automates forensic   bulk-processing of media ... proven with US Federal agencies to provide an "Order ... of suspects. Allevate Limited and Tygart ...
... The Howard Hughes Medical Institute (HHMI) has announced the ... of HHMI Investigators.The appointment ranks as one of the ... research scientist. Dr. Nudler, the Julie Wilson Anderson Professor ... Pharmacology at NYU Langone Medical Center, was selected among ...
Cached Biology News:Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3Revolutionary Face Recognition Media Exploitation System Now Available to Enhance Public Safety in Europe 2Revolutionary Face Recognition Media Exploitation System Now Available to Enhance Public Safety in Europe 3Revolutionary Face Recognition Media Exploitation System Now Available to Enhance Public Safety in Europe 4NYU Langone Medical Center researcher named Howard Hughes Investigator 2
... Hybaid's unique Electro-4 design allows "4 gels ... it is possible to run 200,samples or ... stacking up to four,horizontal gels. To ensure ... to the number of gels being run. ...
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
Biology Products: